Authors: J P Esser E P Krenning J J M Teunissen P P M Kooij A L H van Gameren W H Bakker D J Kwekkeboom
Publish Date: 2006/07/18
Volume: 33, Issue: 11, Pages: 1346-1351
Abstract
Patients with somatostatin receptor subtype 2positive metastasised neuroendocrine tumours can be treated with 177LuDOTA0Tyr3octreotate Some use octreotide as the peptide for peptide receptor radionuclide therapy PRRT We compared in seven patients 177LuDOTA0Tyr3octreotide 177LuDOTATOC and 177LuDOTA0Tyr3octreotate 177LuDOTATATE to see which peptide should be preferred for PRRT with 177LuIn the same patients 3700 MBq 177LuDOTATOC and 3700 MBq 177LuDOTATATE was administered in separate therapy sessions Amino acids were coadministered Wholebody scanning was performed on days 1 4 and 7 post therapy Blood and urine samples were collected We calculated residence times for tumours spleen and kidneysAll patients had longer residence times in spleen kidneys and tumours after use of 177LuDOTATATE p=0016 in each case Comparing 177LuDOTATATE with 177LuDOTATOC the mean residence time ratio was 21 for tumour 15 for spleen and 14 for kidneys Doselimiting factors for PRRT are bone marrow and/or kidney dose Although the residence time for kidneys was longer when using 177LuDOTATATE the mean administered dose to tumours would still be advantageous by a factor of 15 assuming a fixed maximum kidney dose is reached Plasma radioactivity after 177LuDOTATATE was comparable to that after 177LuDOTATOC Urinary excretion of radioactivity was comparable during the first 6 h thereafter there was a significant advantage for 177LuDOTATOC
Keywords: